Comparing the impact of dose reductions and delays on ovarian cancer patient outcomes with three-weekly versus dose dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort.

Tharani Sivakumaran,George Au-Yeung,Linda R Mileshkin,Penelope M Webb,Peter T Grant,Michael Friedlander

doi:10.1200/jco.2018.36.15_suppl.5568

Comparing the impact of dose reductions and delays on ovarian cancer patient outcomes with three-weekly versus dose dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort.

Tharani Sivakumaran, George Au-Yeung + Show 4 more

https://doi.org/10.1200/jco.2018.36.15_suppl.5568

Copy DOI

Journal: Journal of Clinical Oncology

Publication Date: May 20, 2018

Affiliation: Peter MacCallum Cancer Centre, QIMR Berghofer Medical Research Institute, Mercy Hospital for Women, Prince of Wales Hospital

#Ovarian Cancer Patient Outcomes #Chemotherapy Dose Reductions + Show 8 more

Abstract
Full-Text
Similar Papers

Abstract

5568Background: To determine if chemotherapy dose reductions and delays in the adjuvant setting impact ovarian cancer pt outcomes. Secondary objective is comparing deliverability of three weekly an...

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal of Clinical Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.